David Zaccardelli Sells 46,888 Shares of Verona Pharma plc (NASDAQ:VRNA) Stock

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli sold 46,888 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $4.38, for a total transaction of $205,369.44. Following the sale, the chief executive officer now owns 15,298,896 shares in the company, valued at approximately $67,009,164.48. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

David Zaccardelli also recently made the following trade(s):

• On Monday, November 4th, David Zaccardelli sold 94,144 shares of Verona Pharma stock. The stock was sold at an average price of $4.39, for a total transaction of $413,292.16.
• On Friday, October 25th, David Zaccardelli sold 4,800 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $21,024.00.
• On Wednesday, October 23rd, David Zaccardelli sold 16 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $70.08.
• On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $483,797.28.
• On Friday, October 18th, David Zaccardelli sold 245,784 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $1,076,533.92.

Verona Pharma Stock Down 2.1 %

Shares of NASDAQ VRNA opened at $37.59 on Thursday. The stock has a market capitalization of $3.05 billion, a price-to-earnings ratio of -19.58 and a beta of 0.42. Verona Pharma plc has a 12-month low of $11.39 and a 12-month high of $39.40. The company has a current ratio of 8.61, a quick ratio of 8.61 and a debt-to-equity ratio of 0.72. The firm’s 50-day moving average price is $31.28 and its 200-day moving average price is $22.59.

Verona Pharma (NASDAQ:VRNA) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.12). The firm had revenue of $5.62 million during the quarter, compared to analyst estimates of $2.31 million. During the same period last year, the firm earned ($0.18) earnings per share. On average, equities research analysts anticipate that Verona Pharma plc will post -2.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Jennison Associates LLC raised its stake in shares of Verona Pharma by 0.5% in the first quarter. Jennison Associates LLC now owns 1,593,833 shares of the company’s stock valued at $25,645,000 after acquiring an additional 8,448 shares during the period. Sei Investments Co. lifted its stake in Verona Pharma by 3.7% in the first quarter. Sei Investments Co. now owns 74,294 shares of the company’s stock worth $1,195,000 after purchasing an additional 2,640 shares during the last quarter. Capstone Investment Advisors LLC purchased a new position in shares of Verona Pharma during the first quarter valued at approximately $412,000. Bellevue Group AG grew its stake in shares of Verona Pharma by 35.6% during the first quarter. Bellevue Group AG now owns 1,139,295 shares of the company’s stock valued at $18,331,000 after buying an additional 299,299 shares during the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Verona Pharma in the second quarter worth approximately $859,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. HC Wainwright boosted their target price on shares of Verona Pharma from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday. Truist Financial boosted their price target on shares of Verona Pharma from $38.00 to $44.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Canaccord Genuity Group raised their price objective on Verona Pharma from $37.00 to $44.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Wells Fargo & Company boosted their target price on Verona Pharma from $50.00 to $64.00 and gave the stock an “overweight” rating in a research report on Tuesday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $43.83.

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.